Clinical trial
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
NCT00469209 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00469209 |
|---|---|
| Title | Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients |
| Official title | Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Cephalon Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myeloma |
| Intervention type | Drug |
| Interventions | Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid) |
| Enrollment | 60 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 4, 2007 |
| Last update posted | Sep 24, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: